A non‐randomized clinical trial to evaluate the effect of fingolimod on expanded disability status scale score and number of relapses in relapsing‐remitting multiple sclerosis patients

Overview of attention for article published in Clinical and Translational Medicine, April 2019

Altmetric Badge

About this Attention Score

Average Attention Score compared to outputs of the same age and source

Mentioned by

twitter: 3 X users

Citations

dimensions_citation: 2 Dimensions

Readers on

mendeley: 24 Mendeley

Summary X Dimensions citations

So far, Altmetric has seen 3 X posts from 3 X users, with an upper bound of 1,280 followers.

RT @ingentium_ms: A non-randomized #clinicaltrial to evaluate the effect of fingolimod on expanded disability status scale score and number…

10 Apr 2019

Reply Repost Favourite

A non-randomized #clinicaltrial to evaluate the effect of fingolimod on expanded disability status scale score and number of relapses in relapsing-remitting #multiplesclerosis patients. https://t.co/5VOFjAKLe8

10 Apr 2019

Reply Repost Favourite

A non-randomized clinical trial to evaluate the effect of fingolimod on expanded disability status scale score and number of relapses in relapsing-remitting multiple sclerosis patients. https://t.co/biXWRRY24E #Neuralstemcells

09 Apr 2019

Reply Repost Favourite